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suBACKGROUND Atrial ﬁbrillation (AF) is associated with metabolic stress, which activates adenosine
monophosphate-regulated protein kinase (AMPK).
OBJECTIVES This study sought to examine AMPK response to AF and associated metabolic stress, along with
consequences for atrial cardiomyocyte Ca2þ handling.
METHODS Calcium ion (Ca2þ) transients (CaTs) and cell shortening (CS) were measured in dog and human atrial
cardiomyocytes. AMPK phosphorylation and AMPK association with Ca2þ-handling proteins were evaluated by
immunoblotting and immunoprecipitation.
RESULTS CaT amplitude and CS decreased at 4-min glycolysis inhibition (GI) but returned to baseline at 8 min,
suggesting cellular adaptation to metabolic stress, potentially due to AMPK activation. GI increased AMPK-activating
phosphorylation, and an AMPK inhibitor, compound C (CompC), abolished the adaptation of CaT and CS to GI. The AMPK
activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) increased CaT amplitude and CS, restoring CompC-
induced CaT and CS decreases. CompC decreased L-type calcium channel current (ICa,L), along with ICa,L-triggered CaT
amplitude and sarcoplasmic reticulum (SR) Ca2þ content under voltage clamp conditions in dog cells and suppressed CaT
and ICa,L in human cardiomyocytes. Small interfering ribonucleic acid-based AMPK knockdown decreased CaT amplitude
in neonatal rat cardiomyocytes. L-type Ca2þ channel a subunits coimmunoprecipitated with AMPKa. Atrial AMPK-
activating phosphorylation was enhanced by 1 week of electrically maintained AF in dogs; fractional AMPK phosphory-
lation was increased in paroxysmal AF and reduced in longstanding persistent AF patients.
CONCLUSIONS AMPK is activated by metabolic stress and AF, and helps maintain the intactness of atrial ICa,L, Ca
2þ
handling, and cell contractility. AMPK contributes to the atrial compensatory response to AF-related metabolic stress;
AF-related metabolic responses may be an interesting new therapeutic target. (J Am Coll Cardiol 2015;66:47–58)
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48A denosine monophosphate-activatedprotein kinase (AMPK), a serine/threonine kinase, is a sensor of
cellular energy status and is expressed in
many tissues and cell types, including car-
diomyocytes (1,2). AMPK is composed of a
catalytic a-subunit and regulatory b- and
g-subunits, forming a heterotrimer (1,2). With
metabolic disturbance, AMPK is activated by
phosphorylation in response to increased
AMP/adenosine triphosphate (ATP) ratios; it
modulates downstream signaling to compen-
sate for energy depletion by increasing energy
availability while decreasing energy expendi-
ture (1,2). AMPKalleviates cellular dysfunction
caused by conditions like left ventricularhypertrophy (3), heart failure (3), and ischemia (4).
Cardiac electrophysiology may be regulated by AMPK,
because substantial energy is required for the func-
tional integrity of ion channels, transporters, and ex-
changers (1,2,5). However, the role of AMPK in cardiac
electrophysiology is not fully understood, and almost
nothing is known about its functional role in the atria.SEE PAGE 59The most common sustained clinical arrhythmia,
atrial ﬁbrillation (AF) produces a range of adverse
health outcomes. AF causes atrial calcium ion (Ca2þ)-
handling abnormalities and hypocontractility, which
are important in thrombus formation, therapeutic
resistance, and stroke (6). Metabolomic and proteo-
mic analyses indicate a close relationship between
metabolic dysfunction and AF development (7),
suggesting that AMPK might be activated under AF
conditions in an attempt to compensate for meta-
bolic dysfunction.
We undertook the present study to assess whether
AMPK is activated in left atrial (LA) cardiomyocytes
under metabolic stress conditions; whether AMPK
regulates Ca2þ handling and contractile properties of
LA cardiomyocytes; and whether AMPK is activated
in experimental and clinical AF.
METHODS
ANIMAL AND HUMAN MODELS. LA cardiomyocytes
from 51 mongrel dogs were isolated as describedtudentship. Dr. Dobrev is supported by European Network
TH-2010, proposal 260157), and the European-North American At
D03. All other authors have reported they have no relationships
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
received May 15, 2014; revised manuscript received April 5, 2015previously (8). After cells were isolated, they were
kept in 200 mmol/l Ca2þ-containing Tyrode’s solution
for Ca2þ imaging experiments.
Neonatal rat ventricular cardiomyocytes (NRVM)
were isolated using NRVM isolation system kits (Wor-
thington Biochemical Corp., Lakewood, New Jersey)
and cultured for small interfering RNA (siRNA)-based
AMPK knockdown experiments.
All animal care and handling procedures followed
National Institutes of Health guidelines and were
approved by the Montreal Heart Institute Animals
Research Ethics Committee. Eight mongrel dogs (20 kg
to 36 kg) were divided into control and atrial-
tachypacing groups. Dogs were anesthetized with ke-
tamine (5.3 mg/kg, intravenous [IV])/diazepam (0.25
mg/kg, IV)/isoﬂurane (1.5%), intubated, and venti-
lated. A unipolar pacing lead was inserted into the
right atrial (RA) appendage under ﬂuoroscopic guid-
ance and connected to a pacemaker in the neck. Bi-
polar electrodes were inserted into the right
ventricular apex and RA appendage for electrogram
recording. The pacemaker was programmed to stim-
ulate the RA at 600 beats/min for 1 week with ﬁbril-
latory atrial activity during pacing conﬁrmed by
daily electrocardiographic and intracardiac recordings
(9). On day 7, dogs were anesthetized with mor-
phine (2 mg/kg subcutaneous [SC]) and a-chloralose
(120 mg/kg IV, followed by 29.25 mg/kg/h) and venti-
lated. A median sternotomy was performed, and an
LA-appendage sample was taken from the beating
heart and immediately frozen in liquid nitrogen to
avoid changes in cellular metabolic state.
RA appendages were obtained from 10 sinus rhythm
(control) patients, 7 paroxysmal AF patients (pAF)
(in whom the latest episode was >7 days pre-
operatively), and 9 patients with longstanding, persis-
tent AF (cAF) (>6 months) (Online Table 1) who
underwent open heart surgery for coronary artery and/
or valvular heart disease. Appendages were snap frozen
in liquid nitrogen for biochemical studies. Experi-
mental protocols were approved by the ethics com-
mittee of the Universities of Heidelberg (2011-216N-MA)
and Duisburg-Essen (12-5268-BO). Each patient gave
written informed consent. Atrial cardiomyocytes were
isolated from 4 control patients (Online Table 2) with
enzymatic digestion under Ca2þ-free perfusion as
described previously (10).for Translational Research in Atrial Fibrillation
rial Fibrillation Research Alliance Fondation Leducq
relevant to the contents of this paper to disclose.
ntin Fuster.
, accepted April 23, 2015.
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49Canine LA cardiomyocytes and siRNA-transfected
NRVMs were incubated with Indo-1-AM (5 mmol/l)
(Molecular Probes, Eugene, Oregon) in 100 mmol/l
pluronic F-127 (Molecular Probes) and 0.5% dime-
thylsulfoxide (Sigma-Aldrich, St. Louis, Missouri) for
w5 min and then superfused with Tyrode’s solution.
For human cells, the ﬂuorescent indicator ﬂuo-3 ace-
toxymethyl (Fluo-3-AM) (Molecular Probes) was used
as the ﬂuorescent probe (10 mmol/l, 10-min loading,
30-min de-esteriﬁcation). Fluorescence signal ratios
were digitized and converted to intracellular calcium
concentration ([Ca2þ]i) as previously described
(6,10,11). Cells were ﬁeld stimulated by using 10-ms
1.5-threshold square-wave pulses at 36C  1C. CS
was measured in canine LA cardiomyocyte with a
video edge detector, with edge detection cursors
positioned at both cell ends. All data were based on
the average of 5 consecutive beats.
L-type Ca2þ current (ICa,L) was measured in canine
LA cardiomyocytes and human atrial cardiomyocytes
at 36C  1C in whole-cell ruptured-patch conﬁgu-
ration, along with simultaneous measurement of
corresponding triggered [Ca2þ]i transients, with a
holding potential of 80 mV and a 100-ms ramp pulse
to 40 mV to inactivate the fast Naþ current, followed
by a 100-ms test pulse to þ10 mV at 0.5 Hz (10).
Caffeine-induced Ca2þ transients (CaTs) and cor-
responding sodium-calcium exchange (NCX) cur-
rents were simultaneously recorded in dog LA
cardiomyocytes for quantiﬁcation of sarcoplasmic
reticulum (SR) Ca2þ content, as previously described
(10). Membrane potential was held at 80 mV. SR
Ca2þ content was assessed by rapidly applying
caffeine (10 mmol/l) after 1 min of Ca2þ loading at 0.5
Hz with the ICa,L voltage clamp protocol described
above. Caffeine-induced NCX current was integrated
to calculate SR Ca2þ content (10).
Freshly isolated LA cardiomyocytes from control
dogs were plated onto laminin-coated (20 mg/ml)
4-well culture dishes and maintained at 37C, 95%
O2/5% CO2. After a 3-h incubation in culture medium
(M-199 medium supplemented with 1% insulin-
transferrin-selenium and 1% penicillin/streptomycin)
(Life Technologies, Carlsbad, California), dead and
unattached cardiomyocytes were removed, and
fresh normal Tyrode’s solution or glycolysis-
inhibiting (GI) Tyrode’s solution (with 10 mmol/l
2-deoxyglucose [Sigma-Aldrich] and 10 mmol/l so-
dium pyruvate [Sigma-Aldrich]; glucose-free) was
added. Cells were maintained with or without
ﬁeld stimulation (square-wave 5-ms pulses) at 2 Hz
for 20 min and were then fast frozen for subse-
quent biochemical study (studied in parallel for all
experimental series) (12).Protein samples were extracted, quantiﬁed, sepa-
rated by 8% gel electrophoresis, and transferred to
polyvinylidene-diﬂuoride membranes. Sheep anti-rabbit
immunoglobulin G (IgG) M-280-coated Dynabeads
(Life Technologies) were used for immunoprecipita-
tion. Isolated NRVMs were cultured to 60% to 80%
conﬂuence for siRNA transfection. Cells were main-
tained in culture until RNA extraction and quantitative
polymerase chain reaction. BLOCK-iT Alexa Fluor red
ﬂuorescent control (Life Technologies) was used to
conﬁrm transfection efﬁciency.
ATP and AMP were quantiﬁed by high-performance
liquid chromatography (HPLC). Analytical separa-
tion was performed using a MicroSpher C18 column
(100 mm  4.6 mm; internal diameter, 3 mm; Agilent
Technologies, Santa Clara, California), and peak
identities were conﬁrmed by comparison of sample
peak retention times with those of HPLC-grade nucle-
otide standards. Concentrations were calculated by
comparing the peak area of samples with calibration
curves of peak areas of standard compounds.
STATISTICAL ANALYSIS. All data are mean  SEM.
Two-way analysis of variance (ANOVA) with multiple
group comparisons (Bonferroni-corrected Student t
tests) was applied to data with 2 or more main effect
factors. One-way ANOVA was applied for single main-
effect-factor experiments. Repeated measures ana-
lyses were used when the same set of subjects or
materials was exposed to multiple interventions.
Student t tests were used for comparisons involving
only 2 groups. For multiple comparisons with Bon-
ferroni correction, adjusted p values were calculated
by multiplying original p values by the number of
comparisons (N) performed; values shown are
adjusted values (N  p). A 2-tailed p value of <0.05
was considered statistically signiﬁcant. Additional
Methods details are described in the Online Appendix.
RESULTS
Figures 1A and 1B show representative recordings of
CaT and CS under GI conditions. Diastolic [Ca2þ]i
did not change with GI (Figure 1C). However, CaT
amplitude and CS signiﬁcantly decreased at 4 min
and returned toward baseline at 8 min (Figures 1D
and 1E), suggesting cellular adaptation to meta-
bolic stress. Because AMPK activation might un-
derlie cellular adaptation, we examined the effect
of an AMPK inhibitor, compound C (CompC) (Sigma-
Aldrich) at 10 mmol/l, on CaT and CS under meta-
bolic stress. Figures 1F and 1G show representative
recordings under GI conditions in the presence of
CompC. AMPK blockade caused a large and pro-
gressive decrease in CaT and CS, with contractile
FIGURE 1 CaTs and CS After GI in Absence and Presence of Intact AMPK
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50function becoming destabilized in the presence of
GI plus CompC (Figures 1H to 1J), suggesting that
intact AMPK is essential for atrial cardiomyocyte
adaptation to metabolic stress.
We next directly examined whether LA cardio-
myocyte AMPK was activated (phosphorylated) by
metabolic stress. Figure 2A shows immunoblots of
phosphorylated AMPK, total AMPK, and GAPDHin nonpaced and 2-Hz-paced cells with and without
GI. The phosphorylated AMPK/total AMPK ratio in-
creased slightly with GI or 2-Hz pacing only but quite
substantially with combined GI and 2-Hz pacing
(Figure 2B). Because AMPK is activated in response to
increased AMP/ATP ratio, we quantiﬁed cellular AMP
and ATP by HPLC in GI-exposed and/or 2 Hz-paced
or nonpaced cardiomyocytes. The AMP/ATP ratio
FIGURE 3 Effects of AMPK Inhibition on ICa,L Current and Cellular Ca2þ Handling
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51increased slightly with 2 Hz pacing compared with
that under nonpaced conditions and increased
further with the addition of GI (Online Figure 1).
AMPK EFFECTS. Results shown in Figure 1 suggest
that AMPK is important for maintaining cardio-
myocyte Ca2þ stores, particularly under metabolic
stress. We therefore directly evaluated the effect of
blocking AMPK on SR Ca2þ content by simultaneously
measuring caffeine-induced CaT and NCX currents.
Figure 3A shows representative recordings in the
absence or presence of CompC, respectively. AMPK
blockade signiﬁcantly decreased caffeine-induced
NCX current amplitude and SR Ca2þ content
(Figure 3B) without affecting [Ca2þ]i decay kinetics
(Figure 3C).
We next tested whether the direct AMPK acti-
vator 5-aminoimidazole-4-carboxamide ribonucleo-
tide (AICAR) (1 mmol/l) (Cell Signaling, Danvers,
Massachusetts) affected Ca2þ handling and cell
contraction. CaT and CS were measured in atrial
cardiomyocytes paced at 2 Hz before and afterFIGURE 2 Effects of Metabolic Stress on
AMPK Phosphorylation
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representative recordings. AMPK activation increased
CaT amplitude amd CS but did not change diastolic
[Ca2þ]i (Figures 4C to 4E). We then tested AICAR’s
ability to overcome the effects of AMPK inhibition on
CaT and CS. Preincubation with AICAR partially pre-
vented CompC-induced decreases in CaT amplitude
and CS (Figures 4F to 4J) without affecting diastolic
[Ca2þ]i.
Voltage-gated L-type Ca2þ channels play a critical
role in cardiomyocyte Ca2þ handling and excitation-
contraction coupling (12–14) and have been reportedNT
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52to depend on glycolytically derived ATP for functional
integrity (15). Because AMPK activates the glycolysis
pathway, we hypothesized that AMPK contributes to
the functional regulation of L-type Ca2þ channels. We
therefore simultaneously measured ICa,L and ICa,L-
induced CaTs in the presence or absence of CompC.
Figure 5A shows representative recordings. AMPK
inhibition decreased ICa,L density, causing a parallel
decrease in diastolic [Ca2þ]i and CaT amplitudeFIGURE 4 Effects of AMPK Activation on CaTs and CS
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53primary target for AMPK regulation of cellular Ca2þ
handling.
Recent evidence suggests that AMPK may directly
activate downstream targets like ion channel sub-
units to regulate cell function (16). To examine
whether AMPK interacts physically with Ca2þ-
handling proteins, membrane-protein fractions from
canine LA tissues were immunoprecipitated with
AMPKa antibodies, and then immunoblotting was
performed. RyR2, SERCA2a, and PLB did not immu-
noprecipitate with AMPK (Online Figures 3A to 3D).
However, AMPK coimmunoprecipitated with Cav1.2
(Figure 5E), suggesting that AMPK either directly in-
teracts with ICa,L a-subunits or is colocalized alongFIGURE 5 Interactions Between AMPK and L-type Ca2þ Channels
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Figure 3E).
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54AMPK ACTIVATION IN AF. AF is known to cause atrial
Ca2þ-handling abnormalities and hypocontractility
(6,10,13,14). There are clear metabolic disturbances in
atrial tissue samples from AF patients (7). The rapid
atrial rate in AF and associated increased cellularenergy demand might induce an increase in the AMP/
ATP ratio, activating AMPK. We therefore quantiﬁed
AMPK phosphorylation in LA tissues from dogs main-
tained electrically in AF for 1 week. Figure 7A
shows representative immunoblots for phosphorylated
FIGURE 7 AMPK Activation by 1 Week of AF (Dog Model)
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55(Thr172) AMPK, total AMPK, and GAPDH. AF
signiﬁcantly increased the phosphorylated AMPK/total
AMPK ratio, indicating AMPK activation (Figure 7B).
We also evaluated the expression and phosphory-
lation of AMPK in AF patients. RA appendage tissues
were obtained from sinus rhythm, pAF, and
cAF patients undergoing cardiac surgery. Patient
characteristics are shown in Online Table 2. Fractional
AMPK phosphorylation at the Thr172 site was in-
creased by w50% in pAF patients (Online Figure 4A).
In contrast, cAF patients showed a signiﬁcant
decrease in fractional AMPK phosphorylation (Online
Figure 4B). However, absolute AMPK phosphoryla-
tion was not signiﬁcantly affected in either group.
DISCUSSION
In the present study, we provide evidence for an
important role of AMPK in regulating LA car-
diomyocyte Ca2þ handling and contractility, particu-
larly in response to metabolic stress. Furthermore,
our data indicate that the functional integrity of ICa,L
requires intact AMPK activity and that AMPK in-
teracts physically with the L-type Ca2þ channel
a-subunit. We also demonstrate that AMPK is acti-
vated in experimental AF. Taken together, our results
indicate that AMPK operates as a metabolic adaptor
to protect the atria against the proﬁbrillatory, and
possibly prothrombotic, consequences resulting from
AF-induced metabolic stress (Central Illustration).
COMPARISONWITH PREVIOUS STUDIES OF CARDIAC
AMPK. Metabolic disturbances and associated elec-
tromechanical coupling abnormalities play a signiﬁ-
cant pathophysiological role in many cardiac disease
processes. AMPK is activated by cellular energy
depletion and compensates for metabolic abnormal-
ities by increasing energy generation, and decreasing
energy consumption (1,2). AMPK phosphorylation is
a key activating signal (1,2). Although cardiac elec-
trophysiology is closely linked to metabolic function,
relatively little is known about the control of cardiac
electrical activity by AMPK (2).
Several lines of evidence indicate that AMPK
regulates cardiac contractility. Oliveira et al. (17)
demonstrated that cardiac troponin I (cTnI) is a
substrate for the AMPKg2 subunit in mouse left
ventricular cardiomyocytes. The phosphorylation of
cTnI at Ser150 by the activated AMPK holoenzyme
a1/b1/g2 subunit complex increases myoﬁlament
Ca2þ sensitivity and augments contractility in vitro.
The kinase domain of AMPK is sufﬁcient to phos-
phorylate cTnI at Ser150 in the myoﬁlament lattice
(18). Nixon et al. (19) demonstrated that thephysiologically relevant AMPK complex (a1/b1/g2
subunit) phosphorylates cTnI at Ser150 in vitro
within the myoﬁlament lattice.
We demonstrated that pharmacological phosphor-
ylation of the AMPKa subunit with AICAR increases
contractility in dog atrial cardiomyocytes, an effect
at least partially attributable to an AMPK-dependent
increase in CaT amplitude. Oliveira et al. (17) also
reported that AMPK phosphorylation increases con-
tractility without changing CaT amplitude in mouse
ventricular cardiomyocytes. This discrepancy might
be due to differences in species (mouse vs. dog) and
chambers (ventricle vs. atrium) studied. Even though
CaT amplitude was unchanged, CaT decay kinetics
slowed upon AMPKa phosphorylation in the study
by Oliveira et al. (17), suggesting AMPK effects on
Ca2þ handling.
Kockskamper et al. (20) examined the effect of
intermediates and products of glycolysis on Ca2þ
handling in ferret atrial cardiomyocytes. GI in-
creased diastolic [Ca2þ]i and induced CaT alternans,
followed by decreased CaT amplitude, consistent
with our results. In this study, each intermediate
and end product of glycolysis had a different impact
on cellular Ca2þ handling. Of note, fructose-1,6-
bisphosphate, a glycolysis intermediate regulated
by phosphofructokinase-2, tremendously increased
CENTRAL ILLUSTRATION AMPK, Atrial Ca2þ Handling, and Atrial Fibrillation
Harada, M. et al. J Am Coll Cardiol. 2015; 66(1):47–58.
Aspects we studied directly are boxed. Atrial ﬁbrillation (AF) increases atrial rate, enhancing metabolic demands and inducing metabolic stress. Metabolic stress reduces
ICa,L. Decreased ICa,L reduces sarcoplasmic reticulum Ca
2þ-stores, thus reducing the systolic Ca2þ transient. Decreased ICa,L will also reduce APD, promoting AF, whereas
decreased Ca2þ transients lead to reduced atrial contractility and thereby enhance thrombosis/stroke risk. Metabolic stress interferes with the ability of mitochondrial
respiration to keep up with the enhanced need for ATP, causing an increase in the AMP/ATP ratio. The AMP/ATP ratio is the main factor regulating enzymes that
phosphorylate AMPK; that is, when the ratio rises (indicating metabolic stress), AMPK phosphorylation is increased, activating AMPK. The AMPK activation resulting
from AF-related metabolic stress in turn causes phosphorylation of a host of intracellular targets to reduce energy needs and enhance energy availability, which
compensate the metabolic state. The AMPK-induced metabolic compensation offsets the reductions in ICa,L, Ca
2þ transients, and atrial contractility caused by
metabolic stress. Thus, AMPK is an important contributor to maintaining atrial functional integrity in the face of AF-induced metabolic stress. AMPK ¼ adenosine
monophosphate-regulated protein kinase; APD ¼ action-potential duration; Ca2þ ¼ calcium ion; ICa,L ¼ L-type calcium current.
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56open probability of ryanodine receptors (20). Because
AMPK regulates phosphofructokinase-2 activity,
AMPK activation would be expected to augment SR
Ca2þ release through this mechanism.
We demonstrated that pharmacological AMPK
modulation alters L-type Ca2þ channel function. ATP
derived from glycolysis is preferentially used for
regulation of ICa,L (15). Glycolytic enzymes colocalize
with skeletal muscle Ca2þ channels (21). AMPK acti-
vation increases glycolytic ATP and/or potentially
conserves ATP by turning off anabolic pathways,
which may increase energy available for L-type Ca2þchannel regulation. AMPK inhibits the ion-channel
activity of BKCa (22) and Kir6.2 (23,24) by direct
phosphorylation, whereas it increases the activity of
Kv2.1 (16). In the present study, AMPK was found to
both regulate ICa,L function and physically associate
with Cav1.2 channel subunits. Thus, direct modula-
tion of ion-channel function is an additional potential
pathway for AMPK action in this system. Cav1.2
channel activity is known to be regulated by various
protein kinases/phosphatases including PKA, PKC,
and PP1 (25,26), but to our knowledge, AMPK regu-
lation of Cav1.2 has not previously been reported.
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57POTENTIAL MECHANISMS, NOVELTY, AND SIGNIFICANCE.
The orchestration of ion channels, transporters, and
exchangers requires substantial energy; therefore,
pathological metabolic stress could dysregulate
cellular electrophysiology. AF is associated with
important metabolic abnormalities (7), and cellular
energetic state is closely related to the ability to
sustain AF in dogs with tachycardiomyopathic heart
failure (27). AMPK is activated to compensate for
energy depletion by accelerating glycolysis and fatty-
acid oxidation (1,2). In the present study, AMPK was
hyperphosphorylated in the canine LA by acute
metabolic stress and by 1 week of electrically main-
tained AF. Combined with our studies of Ca2þ
handling, these results point to a potentially impor-
tant compensatory role of AMPK in AF. Ikeda et al.
(28) demonstrated the importance of AMPK in main-
taining cardiac function (28). Knockout of LKB1,
an AMPK kinase implicated in AMPK activation,
decreased AMPK activity and impaired cardiac
contractility in association with reduced PLB and
SERCA2a expression. Of note, the effect of LKB1
knockout was much greater in atrium than in
ventricle, and knockout mice showed substantial
atrial remodeling along with spontaneous AF (28).
We provide evidence showing that AMPK frac-
tional phosphorylation is increased in pAF patients
and decreased in cAF patients. It may be that
enhanced AMPK activity helps to protect pAF patients
from arrhythmia persistence, whereas failure of
AMPK phosphorylation may contribute to the chro-
nicity and therapeutic resistance that characterizes
long-term AF. AMPK activity is reduced with age,
potentially contributing to decreased stress tolerance
in the elderly population (29); AF vulnerability in-
creases with aging (6). Macrophage migration inhibi-
tory factor (MIF) modulates AMPK activation, and
genetic variability in MIF expression may affect
AMPK pathway responsiveness (29). Thus, MIF vari-
ability is a candidate mechanism to explain AMPK
variability and any potential contribution to AF
chronicity.
Progression of AF to increasingly persistent forms
is a major clinical challenge (30). The overall pro-
gression rate from paroxysmal to persistent AF is
approximately 5% per year (30). The factors deter-
mining which patients will progress are poorly
understood, and better therapeutic approaches to
prevent progression are needed (30). The present
study raises the interesting possibilities that AMPK
activation might contribute to resistance to AF pro-
gression and that therapeutic modulation of AMPK
might be useful to prevent AF progression and
improve therapeutic tractability.STUDY LIMITATIONS. We used pharmacological tools
to modulate AMPK and to examine its acute effect
on cellular electrophysiology. However, all pharma-
cological probes, especially kinase inhibitors such
as CompC, are imperfectly speciﬁc, and we cannot
exclude the possibility of off-target effects.
Cellular metabolic state can be altered during
cell isolation and no in vitro system completely
reproduces the complex in vivo milieu; therefore,
our results need to be interpreted cautiously. Addi-
tionally, the metabolic disturbances in clinical AF are
much more complicated than the simple in vitro
model we used here and occur on a complex remod-
eling background.
We provide evidence showing that AMPK phos-
phorylation fraction increases in pAF patients and
decreases in cAF patients; however, absolute AMPK
phosphorylation did not change, and we were unable
to show hyperphosphorylation of AMPK targets. Also,
although we showed an increase in the AMP/ATP ratio
and increased AMPK phosphorylation with metabolic
stress, we did not directly measure AMPK activity.
Further work will be necessary to clarify the state of
AMPK phosphorylation, as well as the relevant tar-
gets, at different phases of AF. Additional studies of
the role of atrial metabolic dysfunction in general,
and of AMPK in particular, in both experimental and
clinical AF models are needed to probe this important
and underexplored area.
We identiﬁed ICa,L as an important mediator of
AMPK effects on Ca2þ handling and cell contractility.
However, participation of other components is not
excluded; indeed, the instability of cell shortening
combined with GI and AMPK inhibition suggests the
contribution of other energy-dependent mechanisms.
Further work will be required to detail all the mech-
anisms by which AMPK contributes to the adaptation
of atrial cardiomyocytes to metabolic stress.
CONCLUSIONS
AF-associated metabolic stress impairs atrial Ca2þ
handling and contractility, but also activates AMPK,
which offsets these deleterious effects. AMPK may be
an interesting new therapeutic target in AF.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: AMPK
contributes to the cellular adaptation to metabolic stress
that has been implicated in the inception and mainte-
nance of AF.
TRANSLATIONAL OUTLOOK: Future studies should
examine the therapeutic impact of interventions such as
AMPK activation that reduce metabolic stress to prevent
progression of the substrate underlying the perpetuation
of AF.
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